150 related articles for article (PubMed ID: 17699432)
1. High sirolimus levels may induce focal segmental glomerulosclerosis de novo.
Letavernier E; Bruneval P; Mandet C; Duong Van Huyen JP; Péraldi MN; Helal I; Noël LH; Legendre C
Clin J Am Soc Nephrol; 2007 Mar; 2(2):326-33. PubMed ID: 17699432
[TBL] [Abstract][Full Text] [Related]
2. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
Bumbea V; Kamar N; Ribes D; Esposito L; Modesto A; Guitard J; Nasou G; Durand D; Rostaing L
Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
[TBL] [Abstract][Full Text] [Related]
3. Proteinuria in transplant patients associated with sirolimus.
Franco AF; Martini D; Abensur H; Noronha IL
Transplant Proc; 2007 Mar; 39(2):449-52. PubMed ID: 17362756
[TBL] [Abstract][Full Text] [Related]
4. mToR inhibitors-induced proteinuria: mechanisms, significance, and management.
Letavernier E; Legendre C
Transplant Rev (Orlando); 2008 Apr; 22(2):125-30. PubMed ID: 18631865
[TBL] [Abstract][Full Text] [Related]
5. Conversion to sirolimus for chronic allograft nephropathy and calcineurin inhibitor toxicity and the adverse effects of sirolimus after conversion.
Sayin B; Karakayali H; Colak T; Sevmis S; Pehlivan S; Demirhan B; Haberal M
Transplant Proc; 2009 Sep; 41(7):2789-93. PubMed ID: 19765436
[TBL] [Abstract][Full Text] [Related]
6. Focal segmental glomerulosclerosis after renal transplantation.
Shimizu A; Higo S; Fujita E; Mii A; Kaneko T
Clin Transplant; 2011 Jul; 25 Suppl 23():6-14. PubMed ID: 21623907
[TBL] [Abstract][Full Text] [Related]
7. Post-transplantation proteinuria and sirolimus.
Izzedine H; Brocheriou I; Frances C
N Engl J Med; 2005 Nov; 353(19):2088-9. PubMed ID: 16282189
[No Abstract] [Full Text] [Related]
8. Reduced podocyte expression of alpha3beta1 integrins and podocyte depletion in patients with primary focal segmental glomerulosclerosis and chronic PAN-treated rats.
Chen CA; Hwang JC; Guh JY; Chang JM; Lai YH; Chen HC
J Lab Clin Med; 2006 Feb; 147(2):74-82. PubMed ID: 16459165
[TBL] [Abstract][Full Text] [Related]
9. Proteinuria after conversion to sirolimus in renal transplant recipients.
Sahin GM; Sahin S; Kantarci G; Ergin H
Transplant Proc; 2006 Dec; 38(10):3473-5. PubMed ID: 17175308
[TBL] [Abstract][Full Text] [Related]
10. Expression of synaptopodin and GLEPP1 as markers of steroid responsiveness in primary focal segmental glomerulosclerosis.
Hirakawa M; Tsuruya K; Yotsueda H; Tokumoto M; Ikeda H; Katafuchi R; Fujimi S; Hirakata H; Iida M
Life Sci; 2006 Jul; 79(8):757-63. PubMed ID: 16564554
[TBL] [Abstract][Full Text] [Related]
11. Unusual post-transplantation recurrence of focal segmental glomerulosclerosis which resolved with cyclosporine but not with sirolimus.
Skhiri H; Morelon E; Noel LH; Mamzer-Bruneel MF; Legendre C; Peraldi MN; Kreis H
Transpl Int; 2005 Apr; 18(4):458-60. PubMed ID: 15773967
[TBL] [Abstract][Full Text] [Related]
12. Focal segmental glomerulosclerosis and renal transplantation.
Crosson JT
Transplant Proc; 2007 Apr; 39(3):737-43. PubMed ID: 17445586
[TBL] [Abstract][Full Text] [Related]
13. Significance of early phenotypic change of glomerular podocytes detected by Pax2 in primary focal segmental glomerulosclerosis.
Ohtaka A; Ootaka T; Sato H; Soma J; Sato T; Saito T; Ito S
Am J Kidney Dis; 2002 Mar; 39(3):475-85. PubMed ID: 11877566
[TBL] [Abstract][Full Text] [Related]
14. Conversion to sirolimus from cyclosporine may induce nephrotic proteinuria and progressive deterioration of renal function in chronic allograft nephropathy patients.
Boratyńska M; Banasik M; Watorek E; Falkiewicz K; Patrzałek D; Szyber P; Klinger M
Transplant Proc; 2006; 38(1):101-4. PubMed ID: 16504675
[TBL] [Abstract][Full Text] [Related]
15. Sirolimus interacts with pathways essential for podocyte integrity.
Letavernier E; Bruneval P; Vandermeersch S; Perez J; Mandet C; Belair MF; Haymann JP; Legendre C; Baud L
Nephrol Dial Transplant; 2009 Feb; 24(2):630-8. PubMed ID: 18927120
[TBL] [Abstract][Full Text] [Related]
16. Rituximab and chronic plasmapheresis therapy of nephrotic syndrome in renal transplantation patients with recurrent focal segmental glomerulosclerosis.
Rodríguez-Ferrero M; Ampuero J; Anaya F
Transplant Proc; 2009; 41(6):2406-8. PubMed ID: 19715934
[TBL] [Abstract][Full Text] [Related]
17. Tubular toxicity in sirolimus- and cyclosporine-based transplant immunosuppression strategies: an ancillary study from a randomized controlled trial.
Franz S; Regeniter A; Hopfer H; Mihatsch M; Dickenmann M
Am J Kidney Dis; 2010 Feb; 55(2):335-43. PubMed ID: 19926370
[TBL] [Abstract][Full Text] [Related]
18. Clinical and morphological prognostic factors in membranous nephropathy: significance of focal segmental glomerulosclerosis.
Dumoulin A; Hill GS; Montseny JJ; Meyrier A
Am J Kidney Dis; 2003 Jan; 41(1):38-48. PubMed ID: 12500220
[TBL] [Abstract][Full Text] [Related]
19. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus.
Fairbanks KD; Eustace JA; Fine D; Thuluvath PJ
Liver Transpl; 2003 Oct; 9(10):1079-85. PubMed ID: 14526403
[TBL] [Abstract][Full Text] [Related]
20. Focal segmental glomerulosclerosis in nephrotic adults: presentation, prognosis, and response to therapy of the histologic variants.
Chun MJ; Korbet SM; Schwartz MM; Lewis EJ
J Am Soc Nephrol; 2004 Aug; 15(8):2169-77. PubMed ID: 15284302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
